These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 34918964)

  • 1. Inhalant Cannabidiol Inhibits Glioblastoma Progression Through Regulation of Tumor Microenvironment.
    Khodadadi H; Salles ÉL; Alptekin A; Mehrabian D; Rutkowski M; Arbab AS; Yeudall WA; Yu JC; Morgan JC; Hess DC; Vaibhav K; Dhandapani KM; Baban B
    Cannabis Cannabinoid Res; 2023 Oct; 8(5):824-834. PubMed ID: 34918964
    [No Abstract]   [Full Text] [Related]  

  • 2. Altering biomolecular condensates as a potential mechanism that mediates cannabidiol effect on glioblastoma.
    Wang LP; Chagas PS; Salles ÉL; Naeini SE; Gouron J; Rogers HM; Khodadadi H; Bhandari B; Alptekin A; Qin X; Vaibhav K; Costigliola V; Hess DC; Dhandapani KM; Arbab AS; Rutkowski MJ; Yu JC; Baban B
    Med Oncol; 2024 May; 41(6):140. PubMed ID: 38713310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of autophagic flux differently modulates cannabidiol-induced death in 2D and 3D glioblastoma cell cultures.
    Ivanov VN; Grabham PW; Wu CC; Hei TK
    Sci Rep; 2020 Feb; 10(1):2687. PubMed ID: 32060308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glioblastoma-instructed microglia transition to heterogeneous phenotypic states with phagocytic and dendritic cell-like features in patient tumors and patient-derived orthotopic xenografts.
    Yabo YA; Moreno-Sanchez PM; Pires-Afonso Y; Kaoma T; Nosirov B; Scafidi A; Ermini L; Lipsa A; Oudin A; Kyriakis D; Grzyb K; Poovathingal SK; Poli A; Muller A; Toth R; Klink B; Berchem G; Berthold C; Hertel F; Mittelbronn M; Heiland DH; Skupin A; Nazarov PV; Niclou SP; Michelucci A; Golebiewska A
    Genome Med; 2024 Apr; 16(1):51. PubMed ID: 38566128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined acetyl-11-keto-β-boswellic acid and radiation treatment inhibited glioblastoma tumor cells.
    Conti S; Vexler A; Edry-Botzer L; Kalich-Philosoph L; Corn BW; Shtraus N; Meir Y; Hagoel L; Shtabsky A; Marmor S; Earon G; Lev-Ari S
    PLoS One; 2018; 13(7):e0198627. PubMed ID: 29969452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study.
    Ali S; Borin TF; Piranlioglu R; Ara R; Lebedyeva I; Angara K; Achyut BR; Arbab AS; Rashid MH
    PLoS One; 2021; 16(2):e0246646. PubMed ID: 33544755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide.
    López-Valero I; Saiz-Ladera C; Torres S; Hernández-Tiedra S; García-Taboada E; Rodríguez-Fornés F; Barba M; Dávila D; Salvador-Tormo N; Guzmán M; Sepúlveda JM; Sánchez-Gómez P; Lorente M; Velasco G
    Biochem Pharmacol; 2018 Nov; 157():266-274. PubMed ID: 30195736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immune cell landscape of glioblastoma patients highlights a myeloid-enriched and immune suppressed microenvironment compared to metastatic brain tumors.
    Musca B; Russo MG; Tushe A; Magri S; Battaggia G; Pinton L; Bonaudo C; Della Puppa A; Mandruzzato S
    Front Immunol; 2023; 14():1236824. PubMed ID: 37936683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhalant cannabidiol impedes tumor growth through decreased tumor stemness and impaired angiogenic switch in NCI-H1437-induced human lung cancer model.
    Salles ÉL; Naeini SE; Khodadadi H; Bhandari B; Rezaee S; Threlkeld E; Rogers HM; Costigliola V; Terry AV; Hess DC; Deb S; Deb SP; Yeudall WA; Yu JC; Wang LP; Baban B
    Hum Cell; 2023 May; 36(3):1204-1210. PubMed ID: 36737540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autophagy in glioblastoma: A mechanistic perspective.
    Meena D; Jha S
    Int J Cancer; 2024 Aug; 155(4):605-617. PubMed ID: 38716809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The N
    Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
    Front Immunol; 2021; 12():653711. PubMed ID: 34354698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibiting interferon-γ induced cancer intrinsic TNFRSF14 elevation restrains the malignant progression of glioblastoma.
    Han Y; Zou C; Liu T; Cheng W; Cheng P; Wu A
    J Exp Clin Cancer Res; 2024 Jul; 43(1):212. PubMed ID: 39085878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics.
    Ye Z; Ai X; Zhao L; Fei F; Wang P; Zhou S
    Oncogene; 2021 Oct; 40(42):6059-6070. PubMed ID: 34556813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents.
    Nabissi M; Morelli MB; Santoni M; Santoni G
    Carcinogenesis; 2013 Jan; 34(1):48-57. PubMed ID: 23079154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applications of nanotechnology in remodeling the tumour microenvironment for glioblastoma treatment.
    Mu Y; Zhang Z; Zhou H; Ma L; Wang DA
    Biomater Sci; 2024 Aug; 12(16):4045-4064. PubMed ID: 38993162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy.
    White K; Connor K; Meylan M; Bougoüin A; Salvucci M; Bielle F; O'Farrell AC; Sweeney K; Weng L; Bergers G; Dicker P; Ashley DM; Lipp ES; Low JT; Zhao J; Wen P; Prins R; Verreault M; Idbaih A; Biswas A; Prehn JHM; Lambrechts D; Arijs I; Lodi F; Dilcan G; Lamfers M; Leenstra S; Fabro F; Ntafoulis I; Kros JM; Cryan J; Brett F; Quissac E; Beausang A; MacNally S; O'Halloran P; Clerkin J; Bacon O; Kremer A; Chi Yen RT; Varn FS; Verhaak RGW; Sautès-Fridman C; Fridman WH; Byrne AT
    Ann Oncol; 2023 Mar; 34(3):300-314. PubMed ID: 36494005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Microenvironment Characterization in Glioblastoma Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures.
    Zhang J; Xiao X; Zhang X; Hua W
    J Mol Neurosci; 2020 May; 70(5):738-750. PubMed ID: 32006162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment.
    Li TF; Li K; Wang C; Liu X; Wen Y; Xu YH; Zhang Q; Zhao QY; Shao M; Li YZ; Han M; Komatsu N; Zhao L; Chen X
    J Control Release; 2017 Dec; 268():128-146. PubMed ID: 29051064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-associated microglia and macrophages in glioblastoma: From basic insights to therapeutic opportunities.
    Wang G; Zhong K; Wang Z; Zhang Z; Tang X; Tong A; Zhou L
    Front Immunol; 2022; 13():964898. PubMed ID: 35967394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric Mouse model to track the migration of bone marrow derived cells in glioblastoma following anti-angiogenic treatments.
    Achyut BR; Shankar A; Iskander AS; Ara R; Knight RA; Scicli AG; Arbab AS
    Cancer Biol Ther; 2016; 17(3):280-90. PubMed ID: 26797476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.